Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
Bent Ejlertsen, Malgorzata K Tuxen, Erik Hugger Jakobsen, Maj-Britt Jensen, Ann Soegaard Knoop, Inger Højris, Marianne Ewertz, Eva Balslev, Hella Danø, Peter Michael Vestlev, Julia Kenholm, Dorte L Nielsen, Troels Bechmann, Michael Andersson, Søren Cold, Hanne Melgaard Nielsen, Else Maae, Dorte Carlsen, Henning T Mouridsen
Dive into the research topics of 'Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial'. Together they form a unique fingerprint.